Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 5.2% – Here’s What Happened

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) were down 5.2% during mid-day trading on Monday . The company traded as low as $18.32 and last traded at $18.32. 573 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 6,970 shares. The stock had previously closed at $19.33.

Analyst Ratings Changes

A number of analysts recently commented on AAPG shares. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. B. Riley Financial began coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Finally, BTIG Research reiterated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Trading Down 2.7%

The business’s 50 day simple moving average is $18.55 and its 200 day simple moving average is $22.26. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth $391,000. Finally, UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.